French biotech ImCheck Therapeutics has announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its lead program, ICT01, a humanized anti-butyrophilin 3A (BTN3A ...

Marseille, France Monday, July 21, 2025, 12:00 Hrs [IST] ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

ImCheck’s ICT01 Receives FDA Orphan Drug Designation Clinical data showing unprecedented remission rates in newly diagnosed ...

Fort Worth, TX, July 18, 2025 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE ...